Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Having A Higher Purpose In Life Reduces Risk Of Death Among Older Adults
Possessing a greater purpose in life is associated with lower mortality rates among older adults according to a new study by researchers at Rush University Medical Center.
generic viagra online
New Treatment Option At The Sarah Cannon Cancer Center Provides Hope For Inoperable Tumors
The Sarah Cannon Cancer Center (SCCC) at Centennial Medical Center last week began treating patients with a new non-invasive weapon in the battle against cancer. The Sarah Cannon Cancer Center is the first and only cancer center in Middle Tennessee to offer image-guided robotic stereotactic radiosurgery.
News of the day
Exercise Programs Focusing On Muscle Density Could Reduce Disability And Hospitalization Of The Elderly
Older adults who have less strength, poor physical function and low muscle density are at higher risk of being hospitalized compared to adults with more strength and better function. That"s the finding of a new study in the Journal of the American Geriatric Society.
Public Health

Safe New Treatment Combination For Head And Neck Cancer Patients

Patients undergoing treatment for advanced head and neck cancers may respond well to the addition of gefinitib to chemotherapy, according to a study sponsored by the Eastern Cooperative Oncology Group and chaired by Ethan Argiris, M.D., associate professor of medicine, University of Pittsburgh School of Medicine, and co-leader of the Head and Neck Cancer Program of the University of Pittsburgh Cancer Institute (UPCI). The results were disclosed at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) on May 30 in Orlando, Fla. "We found that adding gefinitib to standard chemotherapy was well-tolerated by patients who had already received chemotherapy or were frail," said Dr. Argiris. "We had hoped this study would improve the survival rate of patients, but while gefinitib did postpone spread of the disease, it did not increase survival rates. The finding that the addition of gefinitib to chemotherapy can delay the growth of head and neck cancer suggests a potential beneficial effect from combination therapy." One group of 136 patients in the placebo-controlled study received docetaxel alone, a standard treatment for head and neck cancer. A second group of 134 patients received gefinitib in addition to docetaxel. This was the first phase III randomized trial to examine the addition of gefinitib to chemotherapy for patients with head and neck cancer. Gefinitib, which also is known by the trade name Iressa, is a targeted therapy against the epidermal growth factor receptor (EGFR) with fewer side effects than traditional chemotherapies. Patients were able to take the drug orally and tolerated it well. Dr. Argiris plans to conduct further studies to identify the subsets of patients most likely to respond to the drug and to examine patients" quality of life while taking the combination therapy. Head and neck cancers are a group of biologically similar cancers originating from the upper aerodigestive tract, including the lip, mouth, nasal cavity, paranasal sinuses, pharynx and larynx that affect more than 45,000 individuals in the U.S. each year. Head and neck cancers are strongly associated with environmental and lifestyle risk factors, including tobacco smoking, alcohol consumption and certain strains of the sexually transmitted human papilloma virus. Courtney McCrimmon University of Pittsburgh Schools of the Health Sciences


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009